PDCD1 and nonpapillary renal cell carcinoma: It is worth noting that the United States Food and Drug Administration has approved belzutifan (a HIF-2α inhibitors) for the treatment of advanced ccRCC patients who have experienced disease progression after receiving PD-1/PD-L1 inhibitors and vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) [42].